Read Microsoft Word - 21.doc text version

:

: : : 27372181-8444 : 252

21

~Requip® Film-coated Tablets / ~Nasacort AQ® / - Requip® Film-coated Tablets

: Ropinirole 0.251.02.0 5.0 ropinirole

: Ropinirole ergoline Ropinirole : (idiopathic Parkinson's Disease)

: --Ropinirole -- ropinirole levodopa levodopa Ropinirole 0.25 :

1

1

2

3

4

0.25 0.5 0.75 1.0

3 3 9 ropinirole 24 24 ropinirole L-dopa L-dopa 20%(dopamine agonist) ropinirole ropinirole ropinirole 65 ropinirole ropinirole

: ropinirole sulpiride metoclopramide ropinirole ropinirole Ropinirole P450 CYP1A2 ciprofloxacin ropinirole AUC Cmax. ropinirole CYP1A2 ( CiprofloxacinEnoxacin Fluvoxamine) ropinirole

: ropinirole Ropinirole Ropinirole

2

: ropinirole : : ropinirole

3

~Nasacort AQ® . Triamcinolone acetonide(USP) Nasacort® AQ :434.51:9-Flouro-11,16,17,21,-tetrahydroxypregna-1,4diene-3,20-dione cyclic 16,17-acetol acetone(C24H31FO6)Nasacort® AQ (thixotropic) triamcinolone acetonide microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, dextrose,benzalkonium chlorid edetate disodium hydrochloric acid sodium droxide 5.0( 4.5-6.0) triamcinolone acetonide 55 55 16.5 120 120 triamcinolone acetonide 120 triamcinolone acetonide 9.075

.

. : 12 : 220 6-12 : 110 220 Nasacort® AQ 6 6

. 220

4

110

. 1483 triamcinolone acetonide 51 ( 2-5 )1394 Nasacort® AQ 19 Triamcinolone acetonide(N=857) % 5.1 2.7 2.1 (N=962)% 3.6 0.8 1.5

. : triamcinolone acetonide (candida albicans) Nasacort® AQ Nasacort® AQ

. C

.

5

triamcinolone acetonide corticosteroid Nasacort® AQ

.

. Nasacort AQ (Triamcinolone acetonide) Nasal Sparay Peak level:0.5ng/ml Vd:99.5/hour Tmax:1.5hours Half-life:3.3hours Flixonase AQ (Fluticasone Propionate) Nasal Sparay Vd:3.7L/kg Protein binding:91% Half-life:3hours Bioavailability<2% Pulmicort AQ (Budesonide) Nasal Sparay Tmax:0.7hours Metabolized by liver with P450 Half-life:2-3hours Bioavailability<10% Similar to Placebo High incidence of epistaxis FDA C 12 : 110-220mcg/QD/day (2-4 doses/day) 6-12 :110ug/QD/Day C High HPA axis potential risk C

12 : 12 200-400mcg/QD/day (4-8 doses/day) 6-12 :100200mcg/QD/Day : 200400mcg/BID/day (4-8 doses/day)

6

220/ug/QD/Day

6-12 : 100200 mcg/BID/Day

NTD 11.87-23.73/day (Average 30 days/Bottle)

NTD 11.87-23.73/day (Average 15days/Bottle)

NTD 15-30/Day (Average 25 day/ Bottle)

1.HPA axis suppression potential 2.Contact dermatitis report (hypersensitivity) 3.Behavior disturbance 4.Special consideration in patients with lung TB

1.Caution in use for patients 1.High incidence of with active or quiescent TB ,or untreated infections adrenal (HPA)suppression 2.

2. Caution in use for patients in recently undergo nasal septal ulcers or trauma 3.Reduce growth velocity in children or teenagers 4.Localized infections of the nose and pharynx with

Candida albicans

1.Thixotropic

formulation

2. 12-16 3.

7

4.

5. 1.PDR1999 1.PDR1999 1.PDR1999 32

2. 2. 2.Martindale 3.Martindale p.1050 32 edition 3.Martindale 32 edition edition p.1034 p.1042

8

Information

Microsoft Word - 21.doc

8 pages

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate

780162


Notice: fwrite(): send of 215 bytes failed with errno=104 Connection reset by peer in /home/readbag.com/web/sphinxapi.php on line 531